Search - tctmd.com

Displaying 541 - 560 of 664

Sort: Relevancy | Date

News Daily News

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

April 14, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Daily News

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

Jason Kahn

February 20, 2014

News Daily News

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

February 12, 2014

News Daily News

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

January 09, 2014

News Daily News

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

January 01, 2014

News Daily News

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

December 30, 2013

Presentation TCT 2013

Vascular Healing in the Setting of Drug Deposition via Paclitaxel-Coated Balloon Delivery: Biological Implications for Device Development

Presenter: Michael Joner

October 31, 2013

Presentation TCT 2013

PRO: Improved Vessel Patency Make Drug-Coated Balloons the Device of Choice for BTK Intervention!

Presenter: Thomas Zeller

October 31, 2013

Presentation TCT 2013

Impact of Lesion Complexity on Outcomes in Drug-Coated Balloon Trials: Implications for Device Selection and Future Trial Design

Presenter: Gunnar Tepe

October 31, 2013

Presentation TCT 2013

Atherectomy and Drug-Coated Balloons: Device Selection, Technical Pitfalls and Available Data

Presenter: Erwin Blessing

October 31, 2013

Presentation TCT 2013

Pushing the Envelope: BVS as a Workhorse Device (With Case Examples)

Presenter: Samer Mansour

October 30, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

Presentation TCT 2013

TCT-17. Current Perspectives On Stent Fractures: Trends, Characteristics And Outcomes From The Food And Drug Administration Manufacturer And User Facility Device Experience...

Presenter: Al Fazir Omar

October 29, 2013

Presentation TCT 2013

TCT-34. The appearance of jailed side branches post-procedure, at 6, 12, 24 and 36 months following implantation of bioresorbable vascular devices – Insights from the ABSORB...

Presenter: Yoshinobu Onuma

October 29, 2013

Presentation TCT 2013

Critical Examination of Current Clinical Outcomes with Best-in-Class Contemporary Permanent Polymer Metallic DES: Can New Devices Improve upon These Results?

Presenter: Ran Kornowski

October 27, 2013

Presentation TCT 2013

Update on the DREAMS Paclitaxel-eluting and Sirolimus-eluting Magnesium Scaffolds: Device Design, Elution Kinetics, Imaging and Extended Clinical Results

Presenter: Michael Haude

October 27, 2013

Presentation TCT 2013

ReZolve Sirolimus-eluting BRS Based on an Iodinated Tyrosine Derivative: Device Iteration and Extended Imaging and Clinical Results

Presenter: Ricardo Costa

October 27, 2013

Presentation TCT 2013

DESyneBD Novolimus-Eluting Coronary Stent: Device Design and Extended Clinical Study Follow-up

Presenter: Ricardo Costa

October 27, 2013

Advertisement

Drug-Eluting Balloon Provides Strong Primary Patency in SFA at 1 Year

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

First-Generation Bioresorbable Stent Performs Well in SFA Lesions

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

EES Reduce Revascularization vs. BMS Regardless of Kidney Disease Severity

Meta-analysis: Newer-Generation DES Safe, Effective vs. BMS in STEMI

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

Vascular Healing in the Setting of Drug Deposition via Paclitaxel-Coated Balloon Delivery: Biological Implications for Device Development

PRO: Improved Vessel Patency Make Drug-Coated Balloons the Device of Choice for BTK Intervention!

Impact of Lesion Complexity on Outcomes in Drug-Coated Balloon Trials: Implications for Device Selection and Future Trial Design

Atherectomy and Drug-Coated Balloons: Device Selection, Technical Pitfalls and Available Data

Pushing the Envelope: BVS as a Workhorse Device (With Case Examples)

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

TCT-17. Current Perspectives On Stent Fractures: Trends, Characteristics And Outcomes From The Food And Drug Administration Manufacturer And User Facility Device Experience...

TCT-34. The appearance of jailed side branches post-procedure, at 6, 12, 24 and 36 months following implantation of bioresorbable vascular devices – Insights from the ABSORB...

Critical Examination of Current Clinical Outcomes with Best-in-Class Contemporary Permanent Polymer Metallic DES: Can New Devices Improve upon These Results?

Update on the DREAMS Paclitaxel-eluting and Sirolimus-eluting Magnesium Scaffolds: Device Design, Elution Kinetics, Imaging and Extended Clinical Results

ReZolve Sirolimus-eluting BRS Based on an Iodinated Tyrosine Derivative: Device Iteration and Extended Imaging and Clinical Results

DESyneBD Novolimus-Eluting Coronary Stent: Device Design and Extended Clinical Study Follow-up

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content